一文看遍！这些ASH最新抗癌进展值得关注( 四 )

CD20靶向CARγδ-T细胞疗法治疗LBCL患者结果出色
AdicetBio公布其同种异体、“现货型”CD20靶向CARγδ-T细胞疗法ADI-001 ，用于治疗R/RB细胞非霍奇金淋巴瘤（NHL）的最新剂量递增临床1期试验数据。分析显示，在所有剂量当中， ADI-001达成75%的ORR以及69%的CR ，并展现良好的安全性。值得一提的是，在之前曾接受过靶向CD19CAR-T疗法的5位LBCL患者中，达成了100%（5/5）的ORR与CR 。此外，在接受剂量水平3或以上的LBCL患者中，亦达成了86%的CR 。
BMS靶向GPRC5D自体CAR-T疗法展现早期疗效成果
BMS公布其靶向GPRC5D自体CAR-T疗法BMS-986393于治疗RRMM患者的临床1期最新数据。在进行中期分析时， BMS-986393展现良好的安全性，所出现的CRS多数低级别、暂时性。在中位追踪期5.82个月的患者分析中，患者达到89.5%的ORR（17/19）以及47.4%（9/19）的CR 。
希望这些亮眼的临床数据，能够尽早转化为临床应用治疗，为更多血液肿瘤的病患改善生活品质与治疗结果！
??
?
?
参考资料：
[1]Real-WorldStudyShowsPatientsTreatedwithIMBRUVICA?(ibrutinib)WereLessLikelytoInitiateaNext-LineTreatmentthanPatientsonAcalabrutinibinFirst-lineChronicLymphocyticLeukemia.RetrievedDecember12,2022fromhttps://www.jnj.com/real-world-study-shows-patients-treated-with-imbruvica-ibrutinib-were-less-likely-to-initiate-a-next-line-treatment-than-patients-on-acalabrutinib-in-first-line-chronic-lymphocytic-leukemia
[2]COGENTBIOSCIENCESANNOUNCESPOSITIVEUPDATEDCLINICALDATAFROMONGOINGPHASE2APEXTRIALEVALUATINGBEZUCLASTINIBINPATIENTSWITHADVANCEDSYSTEMICMASTOCYTOSIS(ADVSM).RetrievedDecember12,2022fromhttps://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-positive-updated-clinical-data
[3]AbbViePresentsDataatthe64thAmericanSocietyofHematology(ASH)AnnualMeetingforInvestigationalNavitoclaxinCombinationWithRuxolitinibforJAKInhibitor-Na?veMyelofibrosisPatients.RetrievedDecember12,2022fromhttps://news.abbvie.com/news/press-releases/abbvie-presents-data-at-64th-american-society-hematology-ash-annual-meeting-for-investigational-navitoclax-in-combination-with-ruxolitinib-for-jak-inhibitor-nave-myelofibrosis-patients.htm
[4]LoxoOncologyatLillyAnnouncesUpdatedDatafromthePhase1/2BRUINClinicalTrialforPirtobrutinibattheAmericanSocietyofHematologyAnnualMeeting.RetrievedDecember12,2022fromhttps://investor.lilly.com/news-releases/news-release-details/loxo-oncology-lilly-announces-updated-data-phase-12-bruin-1
[5]BristolMyersSquibbAnnouncesFirstDisclosuresandNewDataatASH2022,DemonstratingCommitmenttoRaisingStandardsinTreatmentThroughBroadMultipleMyelomaPortfolio.RetrievedDecember12,2022fromhttps://news.bms.com/news/corporate-financial/2022/Bristol-Myers-Squibb-Announces-First-Disclosures-and-New-Data-at-ASH-2022-Demonstrating-Commitment-to-Raising-Standards-in-Treatment-Through-Broad-Multiple-Myeloma-Portfolio/default.aspx
[6]KymeraTherapeuticsPresentsPreclinicalDataDemonstratingActivityofKT-253,aSelectiveHeterobifunctionalMDM2Degrader,inAcuteMyeloidLeukemiaattheAmericanSocietyofHematologyAnnualMeetingRetrievedDecember12,2022fromhttps://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-presents-preclinical-data-demonstrating
[7]GenentechPresentsNewandUpdatedDataforPolivyinPreviouslyUntreatedDiffuseLargeB-CellLymphomaatASH2022.RetrievedDecember12,2022fromhttps://www.gene.com/media/press-releases/14976/2022-12-11/genentech-presents-new-and-updated-data-
[8]PfizerPresentsUpdatedFavorableElranatamabDatafromPivotalPhase2MagnetisMM-3Trial.RetrievedDecember12,2022fromhttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-presents-updated-favorable-elranatamab-data-pivotal
[9]PIVOTALODRONEXTAMAB(CD20XCD3)PHASE2DATAINPATIENTSWITHRELAPSED/REFRACTORYDIFFUSELARGEB-CELLLYMPHOMADEBUTATASH.RetrievedDecember12,2022fromhttps://investor.regeneron.com/news-releases/news-release-details/pivotal-odronextamab-cd20xcd3-phase-2-data-patients